ANDA 90072, held by Hikma. Perindopril Erbumine.
As of Nov 16, 2026, ANDA 90072 (Perindopril Erbumine), held by Hikma, was first approved by FDA on Nov 10, 2009, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 10, 2009 | Original application | Approved |
| Perindopril Erbumine2MG · tablet;oral | Perindopril Erbumine | Discontinued |
| Perindopril Erbumine4MG · tablet;oral | Perindopril Erbumine | Discontinued |
| Perindopril Erbumine8MG · tablet;oral | Perindopril Erbumine | Discontinued |
| Jan 27, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 9, 2016 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 4, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 4, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 4, 2015 | Supplement 2Labeling | Approved | None posted |
| Feb 18, 2011 | Supplement 1Labeling | Approved | None posted |
| Nov 10, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters